步长制药(603858.SH)：获得药品补充申请批准通知书

Core Viewpoint - Company has received approval from the National Medical Products Administration for the drug "Xiaolinbaituxian," which will enhance product quality and meet market demand, positively impacting future operations [1][2]. Group 1: Drug Approval and Details - The drug "Xiaolinbaituxian" has been approved for marketing, with the original approval number remaining unchanged [1]. - The marketing authorization holder has been changed from "Shandong Kongfu Pharmaceutical Co., Ltd." to "Shandong Buchang Pharmaceutical Co., Ltd." [1]. - The drug is used for clearing heat and detoxifying, treating symptoms related to lower jiao damp-heat syndrome and non-specific lower urinary tract infections [1]. Group 2: Research and Development Investment - The company has invested approximately 28.15 million RMB in research and development for "Xiaolinbaituxian" and its pill form [1]. - The company emphasizes the importance of drug research and development, maintaining strict quality and safety controls throughout the drug development, manufacturing, and sales processes [2].